CN110650746B - 生物活性复合物的制备 - Google Patents

生物活性复合物的制备 Download PDF

Info

Publication number
CN110650746B
CN110650746B CN201880032057.6A CN201880032057A CN110650746B CN 110650746 B CN110650746 B CN 110650746B CN 201880032057 A CN201880032057 A CN 201880032057A CN 110650746 B CN110650746 B CN 110650746B
Authority
CN
China
Prior art keywords
salt
lactalbumin
complex
alpha
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880032057.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN110650746A (zh
Inventor
阿夫塔卜·纳迪姆
凯瑟琳娜·斯万堡
何俊勋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ha Muleiteyaopinab
Original Assignee
Ha Muleiteyaopinab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ha Muleiteyaopinab filed Critical Ha Muleiteyaopinab
Priority to CN202411849059.8A priority Critical patent/CN119700935A/zh
Publication of CN110650746A publication Critical patent/CN110650746A/zh
Application granted granted Critical
Publication of CN110650746B publication Critical patent/CN110650746B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Water Supply & Treatment (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201880032057.6A 2017-05-14 2018-05-14 生物活性复合物的制备 Active CN110650746B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411849059.8A CN119700935A (zh) 2017-05-14 2018-05-14 生物活性复合物的制备

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1707715.7 2017-05-14
GBGB1707715.7A GB201707715D0 (en) 2017-05-14 2017-05-14 Preperation of biologically active complexes
PCT/EP2018/062396 WO2018210759A1 (en) 2017-05-14 2018-05-14 Preparation of biologically active complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411849059.8A Division CN119700935A (zh) 2017-05-14 2018-05-14 生物活性复合物的制备

Publications (2)

Publication Number Publication Date
CN110650746A CN110650746A (zh) 2020-01-03
CN110650746B true CN110650746B (zh) 2024-12-31

Family

ID=59201543

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880032057.6A Active CN110650746B (zh) 2017-05-14 2018-05-14 生物活性复合物的制备
CN202411849059.8A Pending CN119700935A (zh) 2017-05-14 2018-05-14 生物活性复合物的制备

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411849059.8A Pending CN119700935A (zh) 2017-05-14 2018-05-14 生物活性复合物的制备

Country Status (13)

Country Link
US (2) US20200140481A1 (enExample)
EP (2) EP3811967B1 (enExample)
JP (2) JP7672122B2 (enExample)
KR (1) KR20200015557A (enExample)
CN (2) CN110650746B (enExample)
AU (1) AU2018269304B2 (enExample)
CA (1) CA3063285A1 (enExample)
DK (2) DK3618848T3 (enExample)
ES (2) ES2861252T3 (enExample)
FI (1) FI3811967T3 (enExample)
GB (1) GB201707715D0 (enExample)
PL (2) PL3811967T3 (enExample)
WO (1) WO2018210759A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes
GB2574845A (en) * 2018-06-20 2019-12-25 Hamlet Pharma Ab Therapeutically active complexes
WO2019243547A1 (en) * 2018-06-20 2019-12-26 Hamlet Pharma Ab Therapeutically active complexes
EP4017522A1 (en) * 2019-08-20 2022-06-29 HAMLET Pharma AB Combination of a chemotherapeutic agent and alpha-lactoglubulin-oleic acid complex for cancer therapy
GB202015836D0 (en) * 2020-10-06 2020-11-18 Hamlet Pharma Ab Compositions
WO2024075003A1 (en) 2022-10-03 2024-04-11 Linnane Pharma Ab A complex comprising a alpha-lactalbumin and a fatty acid or lipid for use in the treatment or prevention of cancer
GB202303177D0 (en) 2023-03-03 2023-04-19 Linnane Pharma Ab Method of predicting response to treatment
WO2025186107A1 (en) 2024-03-04 2025-09-12 Linnane Pharma Ab Therapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670931A2 (en) * 2003-09-05 2006-06-21 GTC Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
EP2385954B1 (en) * 2009-01-09 2013-04-03 HAMLET Pharma AB Complex and production process
WO2010131237A1 (en) 2009-05-13 2010-11-18 Agriculture And Food Development Authority (Teagasc) A process for producing a biologically active globular protein complex
GB0908279D0 (en) 2009-05-14 2009-06-24 Enovate Systems Ltd Subsea winch
US9085643B2 (en) * 2010-11-24 2015-07-21 Hamlet Pharma Ab Biologically active complex and its preparation
ES2676543T3 (es) * 2012-08-09 2018-07-20 Hamlet Pharma Ab Terapia profiláctica y nutracéutica
GB201621752D0 (en) * 2016-12-20 2017-02-01 Hamlet Pharma Ab Therapeutically active complexes
GB201707715D0 (en) 2017-05-14 2017-06-28 Hamlet Pharma Ab Preperation of biologically active complexes

Also Published As

Publication number Publication date
JP7705160B2 (ja) 2025-07-09
US20210130394A1 (en) 2021-05-06
CN119700935A (zh) 2025-03-28
GB201707715D0 (en) 2017-06-28
EP3811967A1 (en) 2021-04-28
PL3618848T3 (pl) 2021-06-14
DK3618848T3 (da) 2021-03-01
JP7672122B2 (ja) 2025-05-07
CN110650746A (zh) 2020-01-03
EP3618848B1 (en) 2020-11-25
US20200140481A1 (en) 2020-05-07
PL3811967T3 (pl) 2024-03-18
WO2018210759A1 (en) 2018-11-22
CA3063285A1 (en) 2018-11-22
US12331073B2 (en) 2025-06-17
AU2018269304B2 (en) 2025-02-27
AU2018269304A1 (en) 2019-11-21
JP2023075290A (ja) 2023-05-30
ES2861252T3 (es) 2021-10-06
EP3811967B1 (en) 2023-12-20
JP2020519673A (ja) 2020-07-02
KR20200015557A (ko) 2020-02-12
DK3811967T3 (da) 2024-01-08
FI3811967T3 (fi) 2023-12-28
ES2973290T3 (es) 2024-06-19
DK3811967T5 (da) 2024-08-19
EP3618848A1 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
CN110650746B (zh) 生物活性复合物的制备
JP2020535138A (ja) グルカゴンおよびｇｌｐ−１受容体の長時間作用型コアゴニスト
JP7580403B2 (ja) Ｇｌｐ１／２二重アゴニストの非経口医薬組成物
US9415114B2 (en) Conformations of divergent peptides with mineral binding affinity
KR102806029B1 (ko) 사이클릭 폴리펩타이드, 그것의 제조 방법 및 치료학적 용도
CN116437946A (zh) 包含展开蛋白的组合物的制备方法
CN110302362B (zh) 一种蛋白在制备预防和治疗糖尿病并发症的药物中的应用
JP2008519785A (ja) 高められた細胞取り込み活性を有する結合体
US10441628B2 (en) High activity tumour inhibitor and preparation method and use thereof
KR102545825B1 (ko) 흥분성 신경 독성 관련 손상 치료를 위한 펩타이드 조성물
Sun et al. Research development, optimization and modifications of anti-cancer peptides
HK40050699A (en) Preparation of biologically active complexes
HK40050699B (en) Preparation of biologically active complexes
WO2018188565A1 (zh) 用于治疗代谢系统疾病的多肽及其组合物
HK40025666A (en) Biologically active complexes and therapeutic uses thereof
HK40025666B (en) Biologically active complexes and therapeutic uses thereof
CN119751562B (zh) 一种胰酶响应的生物活性肽及利用其制备的纳米纤维水凝胶和应用
JP2868800B2 (ja) 癌転移抑制剤
JP2003522116A (ja) 細胞内信号伝達を攪乱させる合成ペプチド
CN116157142A (zh) 肽、肽的盐、药物组合物和生物体组织钙化抑制剂
WO2025142974A1 (ja) 抗癌剤の投与に伴うｉ型アレルギー反応に起因する疾患の予防・治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant